February 03, 2025

Diabetes Drugs Show Equal Kidney Safety

Empagliflozin and dapagliflozin show comparable kidney outcomes in type 2 diabetes, with no clinically important differences in acute kidney injury or CKD progression, according to a large cohort study.

Conexiant

February 03, 2025

SGLT-2 Inhibitors: Cardiovascular Outcomes, Dose-Specific Dapagliflozin Risks

A comparative study highlights the cardiovascular efficacy and safety profiles of sodium-glucose cotransporter 2 inhibitors.

Conexiant

February 03, 2025

PICU Delay Linked to Dialysis Dependency

Researchers analyze kidney replacement therapies in pediatric crush syndrome. Their findings emphasized dialysis dependency and pediatric intensive care unit outcomes post-earthquake.

Conexiant

January 30, 2025

Supine Hypertension: A Missed Opportunity in CVD Prevention?

Study finds supine hypertension independently increases cardiovascular disease risk.

Conexiant

January 29, 2025

Fracture Infection Treatment: Oral vs Intravenous Data

A trial compared oral versus intravenous antibiotics for fracture-related infections.

Conexiant

January 24, 2025

CDC Freezes Calls, Travel Amid Review

The U.S. Department of Health and Human Services has initiated a broad pause in public communications and travel, disrupting meetings, publications, and research funding approvals affecting human and animal health.

Reuters

January 24, 2025

VA Study Maps GLP-1 Effects Across Systems

Large-scale study of 1.9M veterans identifies previously unreported benefits and risks of GLP-1 receptor agonists across 175 health outcomes, including reduced substance use disorders and increased pancreatitis risk.

Conexiant

January 23, 2025

U.S. to Exit WHO by 2026, Impact Looms

President Donald Trump's decision to withdraw the United States from the World Health Organization will impact international health crises and essential programs like tuberculosis and HIV/AIDS treatments.

Reuters

January 22, 2025

Risks and Benefits of GLP-1RAs Evaluated

Analysis of 175 health outcomes highlights the effectiveness and risks of glucagon-like peptide 1 receptor agonists.

Conexiant